Charles River Laboratories International, Inc.
CRL
$162.85
-$5.84-3.46%
NYSE
| 03/28/2026 | 12/27/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.16% | -1.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.16% | -1.06% | |||
| Cost of Revenue | 1.12% | 1.94% | |||
| Gross Profit | -1.77% | -6.61% | |||
| SG&A Expenses | -22.34% | 10.58% | |||
| Depreciation & Amortization | -83.32% | 235.77% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.81% | 11.20% | |||
| Operating Income | 253.71% | -70.33% | |||
| Income Before Tax | 89.82% | -437.27% | |||
| Income Tax Expenses | 14.99% | -156.28% | |||
| Earnings from Continuing Operations | 94.64% | -597.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 84.53% | 76.63% | |||
| Net Income | 94.63% | -608.17% | |||
| EBIT | 253.71% | -70.33% | |||
| EBITDA | 33.09% | 2.64% | |||
| EPS Basic | 94.60% | -608.16% | |||
| Normalized Basic EPS | -75.26% | -66.15% | |||
| EPS Diluted | 94.60% | -610.84% | |||
| Normalized Diluted EPS | -75.26% | -66.00% | |||
| Average Basic Shares Outstanding | -0.54% | 0.01% | |||
| Average Diluted Shares Outstanding | -0.54% | -0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||